The PubMed entry describes a Phase III clinical investigation—named the ADVANCE trial—evaluating induction and concurrent aumolertinib administered with radiotherapy for patients with EGFR‑mutated stage III NSCLC. The article is indexed as a Clinical Trial in Signal Transduct Target Ther, published 21 September 2026 (11:395) with DOI 10.1038/s41392-026-02891-2 and PMID 42764281.
Multiple investigators from Chinese tertiary cancer centers and affiliated hospitals contributed to the work, reflecting a multi‑center collaborative effort. The record identifies several first authors (Nan Bi, Jianyang Wang, Wei Jiang) as having contributed equally; an author from the Division of Quantitative Sciences at Johns Hopkins University appears among the collaborators.
The PubMed summary signals that the ADVANCE study is a randomized phase III trial assessing an induction and concurrent regimen that combines systemic aumolertinib with definitive radiation therapy in locally advanced, EGFR‑mutant non‑small cell lung cancer. The entry further indicates the manuscript reports trial results along with a separate real‑world validation component.
The PubMed page, however, does not present the trial protocol text, randomization schema, primary or secondary endpoints, or statistical analysis plan. These methodological specifics are not available in the provided source content and therefore are not summarized here.
The population described in the title and indexing is patients with EGFR‑mutated stage III NSCLC. The PubMed record does not include the inclusion and exclusion criteria, disease staging subgroups, prior therapies, performance status requirements, or biomarker subtyping beyond the EGFR mutation designation. Those details would be found in the full text of the published article.
According to the PubMed entry, the intervention strategy combined an induction phase and a concurrent phase in which aumolertinib was given with radiotherapy. The record does not report dosing schedules, duration of induction therapy, radiotherapy dose and fractionation, timing of initiation relative to radiation, or any dose‑modification rules. These operational treatment details are not available in the PubMed abstract content.
The publication title and indexing state that the ADVANCE trial results were accompanied by a real‑world validation. The PubMed summary does not specify the size, source, retrospective vs prospective nature, matching or adjustment methods, endpoints used for validation, or follow‑up duration of the real‑world cohort. The record therefore does not permit reporting of the validation methodology from the provided content.
While the study evaluates a systemic targeted agent given concurrently with radiation—an approach with potential safety implications—the PubMed record does not list adverse event rates, grade 3–5 toxicities, pneumonitis frequency, radiation‑related complications, or other safety outcomes. No numerical safety data or comparative toxicity analyses are displayed in the source content.
The PubMed page identifies the manuscript as presenting trial results and real‑world validation; however, the abstract or outcome data (efficacy endpoints such as progression‑free survival, overall survival, locoregional control; hazard ratios; response rates; statistical significance; subgroup results) are not included in the accessible content provided here. As a result, specific conclusions about efficacy or safety cannot be inferred from the PubMed entry alone.
This summary is intentionally limited to the information present in the PubMed record. Key numerical results, detailed methodology, and full discussion are absent from the source content supplied; readers should consult the full article in Signal Transduct Target Ther for comprehensive outcomes, statistical analyses, and clinical interpretation.
Citation metadata available from the PubMed record:
Because the PubMed abstract text and trial data are not displayed in the provided source content, clinicians and researchers seeking full trial design, eligibility, dosing, radiotherapy parameters, efficacy outcomes, safety data, and the methodology and findings of the real‑world validation should retrieve the full manuscript via the journal, DOI, or institutional access.